For many respiratory diseases, such as asthma, COPD, pulmonary fibrosis, COVID-19, etc., Lokib has established an inhalation macromolecular drug platform by taking advantage of the molecular advantages of small molecular weight, stable structure, and less glycosylation modification of nano antibodies. At present, there are three main problems in the development of macromolecular inhaled drug delivery: first, the efficiency of the inhaled drug delivery generator is relatively low, resulting in a large amount of drug waste. This is an important consideration for the relatively expensive macromolecular drugs. The second is the particle size problem. The target sites of drugs for asthma are trachea and bronchus. The median mass diameter (MMAD) of particles emitted by atomizer is required to be 2-5 μ m. It can basically meet the requirements for the deposition of asthma drugs. However, most of the antibody forms with biological activity cannot achieve the particle size distribution that meets the standard. Third, the dose and dosage form of drugs. In the process of atomization, the effective components of drugs will be affected by oxidation, physical degradation, etc. Especially, some macromolecules with biological activity are often inactivated due to atomization. In order to ensure that the drugs can still effectively enter the lung tissue after aerosolization, it is necessary to obtain molecules that meet the stability requirements and provide appropriate preparation buffer conditions.

The research and development platform of inhaled macromolecular drugs independently established by Loqi Biology has perfectly overcome the above three problems, covering asthma, COPD, pulmonary fibrosis and other respiratory diseases; The drug directly reaches the focus, with higher drug utilization rate and less toxic and side effects; Good portability with small atomizer, stable quality before and after atomization. At present, the platform has successfully launched three products. LQ036 - the world's first inhaled nanoantibody drug for the treatment of moderate and severe asthma was officially approved by the Drug Review Center of the State Drug Administration of the People's Republic of China with zero supplement. At present, phase I clinical research is being carried out in China and Australia at the same time. Another product, LQ043, was also submitted to the Chinese clinical phase I IND application in November 2022. At present, the platform of Rocky Biology is in an absolute global leading position, and has a high R&D barrier and access threshold, fully integrating and developing the advantages of various platforms.